6. CLEAN WATER AND SANITATION

Truist Financial Corp Purchases New Stake in BioNTech SE (NASDAQ:BNTX)

Written by Amanda

Truist Financial Corp purchased a new position in BioNTech SE (NASDAQ:BNTXFree Report) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 13,694 shares of the company’s stock, valued at approximately $1,445,000.

A number of other hedge funds have also recently modified their holdings of the company. CWM LLC boosted its holdings in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares during the period. Covestor Ltd purchased a new stake in BioNTech in the 3rd quarter worth approximately $32,000. UMB Bank n.a. bought a new stake in BioNTech in the fourth quarter valued at $50,000. Ramirez Asset Management Inc. bought a new stake in shares of BioNTech during the 3rd quarter valued at about $76,000. Finally, PNC Financial Services Group Inc. boosted its position in BioNTech by 42.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 840 shares of the company’s stock valued at $91,000 after acquiring an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. TD Cowen upped their price target on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. JPMorgan Chase & Co. lowered their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research note on Friday, March 22nd. BMO Capital Markets cut their target price on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 7th. Finally, HC Wainwright raised their price target on BioNTech from $107.00 to $113.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $118.82.

Get Our Latest Research Report on BNTX

BioNTech Trading Down 0.4 %

Shares of NASDAQ:BNTX opened at $91.67 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 9.26. BioNTech SE has a 1 year low of $85.21 and a 1 year high of $125.83. The company has a market cap of $21.79 billion, a P/E ratio of 183.34 and a beta of 0.25. The stock’s fifty day moving average price is $90.55 and its 200-day moving average price is $95.91.

BioNTech (NASDAQ:BNTXGet Free Report) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $2.04 billion. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. Sell-side analysts expect that BioNTech SE will post -2.1 earnings per share for the current year.

BioNTech Profile

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Further Reading

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTXFree Report).



Receive News & Ratings for BioNTech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioNTech and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai